Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2023-03-13 Regulatory Filings
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Confirmation of No Exposure to Silicon Valley Bank
Regulatory Filings Classification · 99% confidence The document is very short (3568 characters) and is clearly identified as an 'RNS Number' announcement from the London Stock Exchange's news service. The content is a brief confirmation regarding the company's lack of exposure to Silicon Valley Bank. This type of short, immediate regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or IR) is best classified as a general Regulatory Filing or announcement. Since 'RNS' is explicitly mentioned as the source and the content is a general regulatory update, the 'RNS' code is the most appropriate fit, acting as the miscellaneous regulatory announcement category.
2023-03-13 English
Creation of New Novel Family of mRNA Therapeutics
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 2195S' and contains standard regulatory announcement formatting, including contact details and an 'RNS' footer indicating it is a release via the London Stock Exchange's news service. The content announces a significant corporate development: the 'Creation of New Novel Family of mRNA Therapeutics' and provides commentary from the CEO. This is a general, material announcement to the market that does not fit the specific definitions of an Earnings Release (ER), Interim Report (IR), Annual Report (10-K), or a specific transaction like Director's Dealing (DIRS) or Capital Change (CAP). Since it is a formal, non-standard regulatory announcement distributed via RNS, the most appropriate classification is the general Regulatory Filings category (RNS). The document length (6297 chars) is substantial enough that it is not merely an announcement *about* a report, but the report itself detailing the news.
2023-03-08 English
Formation of Scientific Advisory Board
Board/Management Information Classification · 99% confidence The document is identified by the RNS Number (9238R) and the header 'RNS Number : 9238R', indicating it is a regulatory news service announcement from the London Stock Exchange. The content announces the 'Formation of Scientific Advisory Board to Support Strategy' and details the experience of the newly appointed professors. This type of announcement, concerning the structure and strategic guidance team (management/advisory board composition), fits best under the Board/Management Information category (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Since it is a specific announcement about management/board structure, MANG is the most precise fit over the general RNS fallback.
2023-03-06 English
Company Presentation
Regulatory Filings Classification · 99% confidence The document is a short announcement (3997 characters) released via RNS, identified by the RNS Number '4155R'. The core content states that the company is announcing an upcoming 'Company Update presentation' and explicitly mentions that 'the presentation is available to download from the Roquefort Therapeutics website'. This structure—a brief notice stating that a presentation document is available elsewhere—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 ('MENU VS MEAL' rule). It is not the presentation itself (which would be an IP), but the announcement of its availability.
2023-03-01 English
Investor Presentation
Report Publication Announcement Classification · 99% confidence The document explicitly states it is an announcement regarding an 'Investor Presentation' where the CEO and Executive Chairman will provide a 'Company Update' via a specific platform (Investor Meet Company). This is a communication aimed at investors about an upcoming presentation, not the presentation material itself, nor is it a formal regulatory filing like a 10-K or an Earnings Release (ER). The content focuses on scheduling an event to present company information. This aligns best with the 'Investor Presentation' definition, which maps to the 'IP' code. Although it is an announcement of a presentation, the content describes the event itself, making 'IP' more specific than 'RPA' or 'RNS'. Given the context of providing details about the presentation content (Company Update) and logistics, 'IP' (Investor Presentation) is the most accurate classification.
2023-02-21 English
Randox Licence and Royalty Agreement
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number : 3604Q' and contains a date stamp typical of regulatory news services. The content announces a specific corporate event: signing an 'exclusive licence and royalty agreement' with Randox Laboratories regarding the Midkine antibody portfolio. This is a material corporate development announcement, not a full financial report (like 10-K or IR), a transcript (CT), or a proxy statement (DEF 14A/PSI). Since it is a specific, material announcement distributed via RNS, and it doesn't fit perfectly into categories like Capital/Financing (CAP) or M&A (TAR), it falls best under the general 'Regulatory Filings' category, which serves as a broad category for significant, non-standard announcements distributed through official channels like RNS, especially when the core event is a partnership/licensing deal. Given the context of RNS distribution, 'RNS' is the most appropriate classification for this type of material news release.
2023-02-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.